arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Aktis Oncology, Inc.

AKTS

$19.69 ▼ -2.41 (-10.90%) at close

6 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

insights

Verdict pending

Sync financial data to generate a health grade for this company.

auto_awesome

Analytical Summary

Review the statement evidence below to form a view on AKTS.

Market Cap $1.1B

Dividend Yield —

Revenue Growth 111.4% ↘

Op. Margin —

ROIC -4.7% ↘

FCF / Share $-0.40 ↗

Trailing P/E —

Price / Book 2.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.38M

↑ +111.4% —

Net Income Profit after all expenses

$-18.32M

↓ -22.3% —

FCF / Share Free cash flow per share

$-0.40

↑ +98.2% —

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Revenue Growth YoY (%)	111.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1292%)	123.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1438%)	—	—	—	—
EPS Growth YoY (%)	98.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	98.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-22.3% Weak Weak Year-over-year change in net income	-22.3% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	98.2% Excellent Excellent Year-over-year change in free cash flow	97.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
FCF / Net Income (x)	1.19x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.42x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	—	1.18x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.29x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Return on Invested Capital (%)	-4.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	14.0% Good Good Return earned on debt + equity capital invested Optimal: > 10%	14.1% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-5.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-3.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-3.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-125%)	-3.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-124%)	—	12.7% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-15%)	14.8% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Net Debt (USD)	$-82.49M	$-371.63M	$-37.78M	$-110.22M	$-58.25M	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Revenue per Share (USD)	$0.06	$0.07	—	$1.98	$1.80	—
Basic EPS, GAAP (USD)	$-0.44	$-0.38	—	$-22.39	$-18.60	—
Free Cash Flow per Share (USD)	$-0.40	$-0.54	—	$-21.94	$-24.04	—
Book Value per Share (USD)	$9.07	$9.48	$-159.68	$-146.41	$-126.03	—
Tangible Book Value per Share (USD)	$9.07	$9.48	$-159.68	$-146.41	$-126.03	—
Basic Weighted Avg Shares (shares)	55.30M	48.63M	—	807,281	805,821	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Working Capital (USD)	$492.41M	$516.03M	$199.07M	—	—	—
Total Equity (USD)	$484.84M	$506.11M	$-146.15M	$-118.20M	$-101.56M	$-87.80M

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Sales/Revenue/Turnover (USD)	$3.38M	$3.23M	—	$1.60M	$1.45M	—
Depreciation Expense (USD)	$879.00K	$652.00K	—	$552.00K	$484.00K	—
Net Income, GAAP (USD)	$-18.32M	$-18.32M	—	$-14.98M	$-14.98M	—
Operating Cash Flow (USD)	$-20.59M	$-24.24M	—	$-16.18M	$-17.48M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday

Aktis Oncology, Inc.

Analytical Summary

6-Year Financial Trajectory

Statement lens

Benchmark Lens

Compare AKTS with peers